4-[(4-硝基苄基)磺酰基]吗啉 | 89303-08-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-[(4-硝基苄基)磺酰基]吗啉
• 中文别名: C.I.分散蓝320(9CI)
• 英文名称: 4-nitrobenzyl 4-morpholinyl sulfone
• 英文别名: 4-[(4-Nitrophenyl)methanesulfonyl]morpholine；4-[(4-nitrophenyl)methylsulfonyl]morpholine
• CAS: 89303-08-2
• 化学式: C₁₁H₁₄N₂O₅S
• 分子量: 286.309
• InChiKey: CXNZLQUNEZFTHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-[(4-硝基苄基)磺酰基]吗啉 在 N-溴代丁二酰亚胺(NBS) 、 palladium 10% on activated carbon 、 氢气 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 7.0h， 生成 2-bromo-4-(morpholine-4-sulfonylmethyl)-phenylamine
  参考文献：
  名称：

  Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors

  摘要：

  Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.09.061
• 作为产物：
  描述：

  硝基苯 、 4-[(氯甲基)磺酰基]吗啉 在 氢氧化钾 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 生成 4-[(2-硝基苯基)甲基磺酰基]吗啉 、 4-[(4-硝基苄基)磺酰基]吗啉
  参考文献：
  名称：

  Reactions of organic anions. Part 109. Vicarious nucleophilic substitution of hydrogen in nitroarenes with carbanions of .alpha.-haloalkyl phenyl sulfones

  摘要：

  DOI：

  10.1021/jo00183a003

文献信息

• MAKOSZA, M.;GOLINSKI, J.;BARAN, J., J. ORG. CHEM., 1984, 49, N 9, 1488-1494
  作者：MAKOSZA, M.、GOLINSKI, J.、BARAN, J.

  DOI：——

  日期：——
• [EN] QUINAZOLIN-2,4-DIAZIRINES AS NPY RECEPTOR ANTAGONIST<br/>[FR] QUINAZOLIN-2,4-DIAZIRINES EN TANT QU'ANTAGONISTE DU RECEPTEUR DU NEUROPEPTIDE Y
  申请人：NOVARTIS AG

  公开号：WO1997020822A1

  公开（公告）日：1997-06-12

  (EN) The invention relates to a method of treatment of disorders and diseases associated with NPY receptor subtype Y5 comprising administering to a warm-blooded animal, including man, in need of such treatment a therapeutically effective amount of a compound of formula (I), in which the variables are as defined and relates to new compounds of formula (I) or a salt thereof, to pharmaceutical compositions, and to the manufacture of new compounds of formula (I) and salts thereof.(FR) L'invention concerne une méthode de traitement de troubles et maladies associés au sous-type Y5 du récepteur du neuropeptide Y, laquelle consiste à administrer à un animal à sang chaud nécessitant un tel traitement, et notamment à l'homme, une dose efficace sur le plan thérapeutique d'un composé de la formule (I) dans laquelle les variables sont telles que définies. L'invention concerne également des nouveaux composés de la formule (I) ou un sel de ceux-ci, des compositions pharmaceutiques ainsi que la fabrication de ces nouveaux composés et des sels de ceux-ci.
• Reactions of organic anions. Part 109. Vicarious nucleophilic substitution of hydrogen in nitroarenes with carbanions of .alpha.-haloalkyl phenyl sulfones
  作者：Mieczyslaw Makosza、Jerzy Golinski、Janusz Baran

  DOI：10.1021/jo00183a003

  日期：1984.5
• Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors
  作者：Carl R. Illig、Carl L. Manthey、Sanath K. Meegalla、Mark J. Wall、Jinsheng Chen、Kenneth J. Wilson、Renee L. DesJarlais、Shelley K. Ballentine、Carsten Schubert、Carl S. Crysler、Yanmin Chen、Christopher J. Molloy、Margery A. Chaikin、Robert R. Donatelli、Edward Yurkow、Zhao Zhou、Mark R. Player、Bruce E. Tomczuk

  DOI：10.1016/j.bmcl.2013.09.061

  日期：2013.12

  Structure-activity relationship (SAR) studies on a highly potent series of arylamide FMS inhibitors were carried out with the aim of improving FMS kinase selectivity, particularly over KIT. Potent compound 17r (FMS IC50 0.7 nM, FMS cell IC50 6.1 nM) was discovered that had good PK properties and a greater than fivefold improvement in selectivity for FMS over KIT kinase in a cellular assay relative to the previously reported clinical candidate 4. This improved selectivity was manifested in vivo by no observed decrease in circulating reticulocytes, a measure of bone safety, at the highest studied dose. Compound 17r was highly active in a mouse pharmacodynamic model and demonstrated disease-modifying effects in a dose-dependent manner in a strep cell wall-induced arthritis model of rheumatoid arthritis in rats. (C) 2013 Elsevier Ltd. All rights reserved.